Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    33.922,16
    +40,66 (+0,12%)
     

  • Dow Jones

    37.838,50
    +63,12 (+0,17%)
     

  • Nasdaq

    15.316,04
    -285,46 (-1,83%)
     

  • Nikkei 225

    37.068,35
    -1.011,35 (-2,66%)
     

  • Petrolio

    82,84
    +0,11 (+0,13%)
     

  • Bitcoin EUR

    59.884,88
    +7,77 (+0,01%)
     

  • CMC Crypto 200

    1.369,48
    +56,86 (+4,33%)
     

  • Oro

    2.407,00
    +9,00 (+0,38%)
     

  • EUR/USD

    1,0648
    +0,0002 (+0,02%)
     

  • S&P 500

    4.966,97
    -44,15 (-0,88%)
     

  • HANG SENG

    16.224,14
    -161,73 (-0,99%)
     

  • Euro Stoxx 50

    4.918,09
    -18,48 (-0,37%)
     

  • EUR/GBP

    0,8600
    +0,0044 (+0,51%)
     

  • EUR/CHF

    0,9686
    -0,0025 (-0,25%)
     

  • EUR/CAD

    1,4646
    -0,0004 (-0,03%)
     

Codexis to Participate in Jefferies Healthcare Conference

Codexis, Inc.
Aggiornato ·1 minuto per la lettura
Codexis, Inc.
Codexis, Inc.

REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Healthcare Conference, being held June 7-9, 2023, in New York, New York.

Management will participate in a fireside chat on Wednesday, June 7, 2023, at 1:00 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay will be archived for 90 days following the event.

About Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing, nucleic acid synthesis and genomic sequencing, and – as biotherapeutic candidates – they have the potential to treat challenging diseases. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing, greater sensitivity in genomic and diagnostic applications and potentially more efficacious therapeutics. For more information, visit www.codexis.com.

For More Information

Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com

Media Contact
Lauren Musto
(781) 572-1147
media@codexis.com